X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (534) 534
male (411) 411
animals (331) 331
oxazines - pharmacokinetics (317) 317
pharmacology & pharmacy (297) 297
female (249) 249
benzoxazines (230) 230
index medicus (217) 217
adult (211) 211
oxazines - pharmacology (210) 210
oxazines - therapeutic use (169) 169
rats (166) 166
oxazines - administration & dosage (138) 138
hiv infections - drug therapy (132) 132
pharmacokinetics (124) 124
middle aged (119) 119
oxazines (118) 118
oxazines - metabolism (116) 116
mice (102) 102
oxazines - blood (102) 102
dose-response relationship, drug (91) 91
infectious diseases (89) 89
ofloxacin (85) 85
oxazines - chemistry (84) 84
oxazines - adverse effects (82) 82
drug interactions (80) 80
administration, oral (77) 77
kinetics (76) 76
efavirenz (72) 72
anti-hiv agents - therapeutic use (71) 71
lactose - analogs & derivatives (70) 70
methylcellulose - analogs & derivatives (70) 70
drug therapy, combination (68) 68
anti-hiv agents - pharmacokinetics (63) 63
chemistry, medicinal (63) 63
reverse transcriptase inhibitors - therapeutic use (62) 62
reverse transcriptase inhibitors - pharmacokinetics (58) 58
immunology (57) 57
chromatography, high pressure liquid (51) 51
aged (50) 50
biochemistry & molecular biology (50) 50
microbiology (48) 48
rats, sprague-dawley (48) 48
analysis (47) 47
metabolism (47) 47
rats, wistar (47) 47
hiv (45) 45
in vitro techniques (44) 44
chemistry, multidisciplinary (43) 43
in-vitro (43) 43
structure-activity relationship (43) 43
area under curve (42) 42
drug administration schedule (42) 42
time factors (42) 42
anti-hiv agents - adverse effects (41) 41
pharmacology/toxicology (41) 41
solubility (41) 41
treatment outcome (41) 41
anti-hiv agents - administration & dosage (40) 40
biological availability (40) 40
hiv infections - virology (39) 39
toxicology (39) 39
anti-hiv agents - blood (38) 38
brain - metabolism (38) 38
drug delivery systems (37) 37
drug therapy (37) 37
hiv infection (37) 37
microbial sensitivity tests (37) 37
drugs (36) 36
half-life (36) 36
neurosciences (35) 35
oxazines - chemical synthesis (35) 35
reverse transcriptase inhibitors - adverse effects (35) 35
anti-bacterial agents - pharmacology (34) 34
anti-infective agents - pharmacokinetics (34) 34
research (34) 34
adolescent (33) 33
antiviral agents (33) 33
virology (33) 33
cytochrome p-450 enzyme system - metabolism (32) 32
cells, cultured (31) 31
hiv-1 (31) 31
protease inhibitors (31) 31
reproducibility of results (31) 31
tablets (31) 31
antiretroviral therapy (30) 30
cell survival - drug effects (30) 30
dogs (30) 30
reverse transcriptase inhibitors - administration & dosage (30) 30
reverse transcriptase inhibitors - blood (30) 30
biotransformation (29) 29
brain - drug effects (29) 29
indinavir (29) 29
nevirapine (29) 29
therapy (29) 29
delayed-action preparations (28) 28
hiv infections - metabolism (28) 28
hiv-1 - drug effects (28) 28
medicine & public health (28) 28
methylcellulose - chemistry (28) 28
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (812) 812
Japanese (25) 25
French (5) 5
German (5) 5
Italian (4) 4
Chinese (3) 3
Dutch (1) 1
Hungarian (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 07/2005, Volume 39, Issue 3, pp. 307 - 312
Efavirenz (EFV) is associated with hyperlipidemia when used in combination with other antiretroviral drugs. EFV is a mixed inducer/inhibitor of cytochrome P450... 
Hydroxymethylglutaryl coenzyme A reductase inhibitors | Nonnucleoside reverse transcriptase inhibitors | HIV infection | Drug interactions | Statins | ORGANIC ANION TRANSPORTER | INFECTIOUS DISEASES | drug interactions | HUMAN PLASMA | DRUG-INTERACTIONS | BIOTRANSFORMATION PRODUCTS | IMMUNOLOGY | hydroxymethylglutaryl coenzyme A reductase inhibitors | HUMAN SERUM | RHABDOMYOLYSIS | nonnucleoside reverse transcriptase inhibitors | MASS-SPECTROMETRY | A REDUCTASE INHIBITORS | LIQUID-CHROMATOGRAPHY | statins | COMBINATION ANTIRETROVIRAL THERAPY | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Pyrroles - pharmacokinetics | Heptanoic Acids - pharmacokinetics | Humans | Male | Benzoxazines | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Cholesterol, LDL - blood | Female | Oxazines - administration & dosage | HIV Seronegativity | Hyperlipidemias - metabolism | Simvastatin - administration & dosage | Anti-HIV Agents - adverse effects | Hyperlipidemias - drug therapy | Simvastatin - pharmacokinetics | Oxazines - adverse effects | Pravastatin - administration & dosage | Hyperlipidemias - etiology | Atorvastatin | HIV Infections - drug therapy | Pravastatin - pharmacokinetics | HIV Infections - metabolism | Dosage and administration | Drug therapy, Combination | Drug therapy | Simvastatin
Journal Article
JAMA, ISSN 0098-7484, 07/2002, Volume 288, Issue 2, pp. 169 - 180
CONTEXT Management of antiretroviral treatment failure in patients receiving protease inhibitor (PI)–containing regimens is a therapeutic challenge. OBJECTIVE... 
MEDICINE, GENERAL & INTERNAL | DRUG-INTERACTIONS | COMBINATION THERAPY | VIROLOGICAL FAILURE | IMMUNODEFICIENCY-VIRUS TYPE-1 | RESISTANCE | SOCIETY-USA PANEL | HIV-1-INFECTED PATIENTS | PLUS INDINAVIR | HIV-INFECTED ADULTS | CLINICAL PHARMACOKINETICS | Humans | Drug Resistance, Viral | Male | Benzoxazines | Saquinavir - therapeutic use | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | HIV Infections - immunology | Oxazines - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Adenine - therapeutic use | HIV Protease Inhibitors - pharmacokinetics | Treatment Failure | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | HIV Protease Inhibitors - adverse effects | Indinavir - pharmacokinetics | Nelfinavir - therapeutic use | Adenine - analogs & derivatives | Double-Blind Method | Anti-HIV Agents - adverse effects | Proportional Hazards Models | CD4 Lymphocyte Count | Adenine - pharmacokinetics | HIV Protease Inhibitors - therapeutic use | Disease Progression | Sulfonamides - pharmacokinetics | Antiretroviral Therapy, Highly Active | Dideoxynucleosides - pharmacokinetics | Organophosphonates | Sulfonamides - therapeutic use | Oxazines - therapeutic use | Anti-HIV Agents - pharmacokinetics | Saquinavir - pharmacokinetics | Carbamates | HIV Infections - drug therapy | Nelfinavir - pharmacokinetics | Indinavir - therapeutic use | Evaluation | Protease inhibitors | Drug therapy | HIV infection | Medical research | Human immunodeficiency virus | HIV
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2016, Volume 18, Issue 5, pp. 483 - 490
Aims To assess the safety and pharmacokinetic and pharmacodynamic characteristics of BI 135585, a selective 11β‐hydroxysteroid dehydrogenase‐1 (11β‐HSD1)... 
antidiabetic drug | drug development | pharmacokinetics | pharmacodynamics | phase I–II study | Glycated Hemoglobin A - analysis | Biomarkers - urine | Liver - enzymology | Humans | Middle Aged | Half-Life | Male | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Oxazines - pharmacokinetics | Pyridones - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Hypoglycemic Agents - administration & dosage | Liver - drug effects | Subcutaneous Fat - drug effects | Adult | Female | Oxazines - administration & dosage | Hydrocortisone - blood | Adrenocorticotropic Hormone - blood | Enzyme Inhibitors - adverse effects | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Double-Blind Method | Pyridones - pharmacokinetics | Diabetes Mellitus, Type 2 - enzymology | Enzyme Inhibitors - pharmacology | Biomarkers - blood | Mineralocorticoids - urine | 11-beta-Hydroxysteroid Dehydrogenase Type 1 - antagonists & inhibitors | Oxazines - adverse effects | 11-beta-Hydroxysteroid Dehydrogenase Type 1 - metabolism | Diabetes Mellitus, Type 2 - blood | Oxazines - therapeutic use | Aged | Pyridones - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucocorticoids - urine | Hypoglycemic Agents - adverse effects | Pyridones - adverse effects | Subcutaneous Fat - enzymology
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 2/2017, Volume 73, Issue 2, pp. 185 - 195
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 02/2006, Volume 61, Issue 2, pp. 148 - 154
Journal Article
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 11/2014, Volume 31, Issue 11, pp. 3060 - 3072
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 1/2008, Volume 25, Issue 1, pp. 194 - 206
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 12/2016, Volume 26, Issue 23, pp. 5695 - 5702
Journal Article